Founded in 2020, VoiceMed develops software that analyses short breathing and voice recordings captured through standard smartphone microphones to surface respiratory risk signals. Its AI models extract vocal biomarkers linked to lung function, enabling device-free, fully digital screening and ongoing monitoring for conditions such as Chronic Obstructive Pulmonary Disease (COPD). The company targets deployment across primary care, hospital-at-home, and other remote programmes, aiming to make respiratory assessment more accessible and scalable. VoiceMed has partnered with Chiesi Group to run a six-month pilot exploring early detection of chronic respiratory diseases and measuring outcomes like Quality Adjusted Life Years (QALY) and reduced emergency visits. With total funding now at €1 million, the firm plans to accelerate clinical studies to validate its home-monitoring solution for COPD and support initial market entry. The fresh capital will specifically fund real-world clinical validation and commercialization activities, positioning VoiceMed for broader adoption in aging-pressured healthcare systems.

Total raised

$1M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2026